PDCD1 and breast carcinoma: Spectra thus identifies a prometastatic gene program that is upregulated following anti-PD-1/PD-L1 treatment in individuals with therapy-resistant breast cancer, with implications for understanding adaptive resistance mechanisms and macrophage polarization.